Hepatitis B virus (HBV) is a viral infection that increases the likelihood of developing liver cancer or liver failure. According to the World Health Organization, an estimated 2 billion people currently are infected with HBV, which is more than 10 times the number of people who have human immunodeficiency virus (HIV). Currently, treatment for hepatitis B infections is limited to one class of drugs that targets the virus. Stefan Sarafianos, an investigator with the University of Missouri Bond Life Sciences Center (BLSC) recently was awarded $3 million from the National Institutes of Health to study the disease. Building on existing research, he and his team will work on the development of new drugs to treat HBV.
“Hepatitis B truly is a global, public health issue,” said Sarafianos, a professor of molecular microbiology and immunology and the Chancellor’s Chair of Excellence in molecular virology in the University of Missouri School of Medicine. “With more than 240 million people chronically infected, it is an epidemic of epic proportions. We are working to develop therapeutic strategies that not only suppress the virus, but also have the potential to eradicate hepatitis B.”
Since HIV and HBV share similar replication characteristics, proven HIV drugs called nucleoside analogs or “nucs,” which target the replication abilities of HIV, also are the treatments of choice for HBV. Based on this knowledge, Sarafianos and his team are working to develop a second drug line that targets the viral capsid, or the building block of an inner protective shell that protects the viruses’ genetic material. The capsid is involved in many aspects of the viral lifecycle and its stability is necessary for HBV.
“Research shows that viral DNA is housed inside the viral capsid,” Sarafianos said. “We work on drugs that would destabilize the viral capsid and could help eradicate the virus. We truly are grateful to the NIH for their continuing support of our efforts.”
“This significant funding from the NIH highlights the research excellence of the School of Medicine and its commitment to solving global health issues,” said Patrick Delafontaine, of the Hugh E. and Sarah D. Stephenson dean of the School of Medicine. “This diverse team of scientists and students showcases the school’s commitment to research and teaching the next generation of scientists. We’re proud to be leading the effort and look forward to results that will benefit the world.”
“The innovative culture at the Bond Life Sciences Center enables our investigators from across the campus, state, nation and the world to solve the health problems affecting global citizens,” said Jack Schultz, director of the MU Bond Life Sciences Center. “The BLSC encourages the development of the research strengths of our scientists, undergraduate and graduate students. We’re excited about this new research and its implications.”
The multi-investigator project, “Taking aim at HBV eradication using novel NRTIs and Capsid effectors,” (Grant #1R01AI121315-01A) will be led by Sarafianos and includes researchers from the University of Minnesota in Minneapolis, Minnesota, and the University of Pittsburgh.
Source: University of Missouri Health
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.